Report Code : CVMI24071736 | Published Date : March 12, 2025
The global veterinary pain management market was valued at USD 2.72 billion in 2023 and is projected to grow at a CAGR of 10.9% through 2031, reaching USD 5.95 billion. This growth is driven by:
- Rising pet ownership: 70% of U.S. households now own a pet pets)
- Increased awareness of animal pain: 85% of vets now assess pain at every examination visit)
- Advances in multimodal pain therapies (30% improved outcomes compared to single-drug therapies) approaches)
Key Segments:
- Pharmaceuticals (NSAIDs, opioids, steroids) – XX% market share
- Therapeutic Devices (laser therapy, TENS units) – XX%
- Nutraceuticals (CBD, glucosamine) – 15%
Growth Drivers
1. Aging Pet Population
- 50% of dogs over 10 years suffer from arthritis
- Feline osteoarthritis diagnoses up 40% since 2020
2. Regulatory Approvals
- FDA’s 2023 clearance of Librela (first monthly osteoarthritis injection for dogs)
- EU’s 2024 guidelines on chronic pain management
3. Cannabis-Derived Products
- VetCBD’s full-spectrum oil reduces post-op pain by 55%
- 25 U.S. states now allow veterinary CBD use
4. Pet Insurance Coverage
- Trupanion’s 2024 policy covers 80% of pain management costs
- 40% increase in claims for chronic pain treatments
Regional Analysis
Region |
Market Share |
Key Trend |
North America |
45% |
70% of vets use pain scoring systems |
Europe |
XX% |
Strict opioid prescription regulations |
Asia-Pacific |
XX% |
Japan’s acupuncture adoption (35% YoY) |
Latin America |
XX% |
Brazil leads in herbal medicine research |
Case Study:
- University of Pennsylvania’s Pain Center reduced opioid use by 60% using laser therapy.
Competitive Landscape
Top 5 Players:
- Zoetis (30% share) – Librela (monthly arthritis injection)
- Elanco (XX%) – Galliprant (targeted NSAID)
- Dechra (XX%) – Tramadol ER for chronic pain
- VetCBD (XX%) – Full-spectrum hemp oil
- Assisi Animal Health (XX%) – Loop laser therapy system
Recent Developments:
- Zoetis’ USD 400M acquisition of pain biomarker startup
- FDA fast-track approval for feline-specific NSAID
Future Outlook
- 2025: Personalized pain vaccines are introduced trials
- 2027: 65% of clinics will implement AI for pain assessment tools
- In 2030, non-opioid therapies are expected to dominate 80% of the market.
Reasons To Buy

Scope

Key Players
- Ceva
- Elanco
- Zoetis
- Vetoquinol
- Boehringer Ingelheim International GmbH
Global Veterinary Pain Management Market Report
- 1. Global Veterinary Pain Management Market Research Report
- 1.1 Study Objectives
- 1.2 Global Veterinary Pain Management Market - Overview
- 1.3 Reason to Read This Report
- 1.4 Methodology and Forecast Analysis
- 2.1 Global Veterinary Pain Management Market Research Report – Detailed Scope and Definitions
- 2.1.1 By Product Type
- 2.1.2 By Animal Type
- 2.1.3 By Distribution Channel
- 2.1.4 By Region
- 3.1. Drivers - Macro-Economic Based, Supply Side, and Demand Side Drivers
- 3.2. Restraints – By Product Type, By Animal Type, By Distribution Channel, By Country
- 3.3. Opportunities – By Product Type, By Animal Type, By Distribution Channel, By Country
- 3.4. Trends – By Product Type, By Animal Type, By Distribution Channel, By Country
- 3.5. PEST Analysis
- 3.6. Porters Five Rule Analysis
- 3.7. Company’s Share Analysis (CSA) by Region or By Country
- 3.8. Global Veterinary Pain Management Market Research Report – DROTs Impact Analysis
- 4.1. Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 4.2. Annual Market Trend Assessment – Year-on-Year (YoY) Growth Analysis (%)
- 4.3. Incremental Market Value/Volume Opportunity between 2019 - 2023 and 2024 - 2031
- 4.4. Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.1 NSAIDs
- 5.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.2 Opioids
- 5.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.3 Anesthetics
- 5.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 5.4 Other Analgesics
- 5.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 5.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 5.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 5.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.1 Dogs
- 6.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.2 Cats
- 6.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.3 Horses
- 6.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 6.4 Others
- 6.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 6.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 6.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 6.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.1 Veterinary Hospitals
- 7.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.2 Veterinary Clinics
- 7.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.3 Retail Pharmacies
- 7.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 7.4 Online Pharmacies
- 7.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 7.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 7.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 7.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.1 North America
- 8.1.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 8.1.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 8.1.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 8.1.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.2 Europe
- 8.2.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 8.2.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 8.2.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 8.2.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.3 Asia-Pacific
- 8.3.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 8.3.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 8.3.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 8.3.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.4 Latin America
- 8.4.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 8.4.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 8.4.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 8.4.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.5 Middle East & Africa
- 8.5.1 Market Performance Review & Future Outlook: Assessing 2019 - 2023 and Predicting 2024 - 2031 Trends (USD Millions)
- 8.5.2 Annual Market Trend Assessment – Yearly Growth Observation (Y-O-Y)(%)
- 8.5.3 Incremental Market Value/Volume Opportunity between 2019 - 2023 and From 2024 to 2031
- 8.5.4 Market Shares Analysis in Years - 2019, 2023, 2024 and 2031
- 8.6 Global Veterinary Pain Management Market - Opportunity Analysis Index, By Product Type, By Animal Type, By Distribution Channel, and Region, 2024 - 2031
- 9.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 9.1.1 NSAIDs
- 9.1.2 Opioids
- 9.1.3 Anesthetics
- 9.1.4 Other Analgesics
- 9.2.1 Dogs
- 9.2.2 Cats
- 9.2.3 Horses
- 9.2.4 Others
- 9.3.1 Veterinary Hospitals
- 9.3.2 Veterinary Clinics
- 9.3.3 Retail Pharmacies
- 9.3.4 Online Pharmacies
- 9.4.1 United States
- 9.4.2 Canada
9.6 Regional Trends Analysis
9.7 North America Global Veterinary Pain Management Market Research Report - Company Profiles- 9.7.1 Company 1 (United States)
- 9.7.2 Company 2 (Canada)
- 9.7.3 Company 3 (Canada)
- 10.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 10.1.1 NSAIDs
- 10.1.2 Opioids
- 10.1.3 Anesthetics
- 10.1.4 Other Analgesics
- 10.2.1 Dogs
- 10.2.2 Cats
- 10.2.3 Horses
- 10.2.4 Others
- 10.3.1 Veterinary Hospitals
- 10.3.2 Veterinary Clinics
- 10.3.3 Retail Pharmacies
- 10.3.4 Online Pharmacies
- 10.4.1 Germany
- 10.4.2 United Kingdom
- 10.4.3 France
- 10.4.4 Spain
- 10.4.5 Italy
- 10.4.6 Russia
- 10.4.7 Netherlands
- 10.4.8 Poland
- 10.4.9 Rest of Europe
10.6 Regional Trends Analysis
10.7 Europe Global Veterinary Pain Management Market Research Report - Company Profiles- 10.7.1 Company 1 (Germany)
- 10.7.2 Company 2 (United Kingdom)
- 10.7.3 Company 3 (United Kingdom)
- 11.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 11.1.1 NSAIDs
- 11.1.2 Opioids
- 11.1.3 Anesthetics
- 11.1.4 Other Analgesics
- 11.2.1 Dogs
- 11.2.2 Cats
- 11.2.3 Horses
- 11.2.4 Others
- 11.3.1 Veterinary Hospitals
- 11.3.2 Veterinary Clinics
- 11.3.3 Retail Pharmacies
- 11.3.4 Online Pharmacies
- 11.4.1 China
- 11.4.2 Japan
- 11.4.3 India
- 11.4.4 South Korea
- 11.4.5 Australia & NZ
- 11.4.6 ASEAN
- 11.4.7 Rest of Asia-Pacific
11.6 Regional Trends Analysis
11.7 Asia-Pacific Global Veterinary Pain Management Market Research Report - Company Profiles- 11.7.1 Company 1 (China)
- 11.7.2 Company 2 (Japan)
- 11.7.3 Company 3 (Japan)
- 12.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 12.1.1 NSAIDs
- 12.1.2 Opioids
- 12.1.3 Anesthetics
- 12.1.4 Other Analgesics
- 12.2.1 Dogs
- 12.2.2 Cats
- 12.2.3 Horses
- 12.2.4 Others
- 12.3.1 Veterinary Hospitals
- 12.3.2 Veterinary Clinics
- 12.3.3 Retail Pharmacies
- 12.3.4 Online Pharmacies
- 12.4.1 Brazil
- 12.4.2 Mexico
- 12.4.3 Argentina
- 12.4.4 Peru
- 12.4.5 Colombia
- 12.4.6 Rest of Latin America
12.6 Regional Trends Analysis
12.7 Latin America Global Veterinary Pain Management Market Research Report - Company Profiles- 12.7.1 Company 1 (Brazil)
- 12.7.2 Company 2 (Mexico)
- 12.7.3 Company 3 (Mexico)
- 13.1 By Product Type Analysis 2019 - 2023 and Forecast, 2024 - 2031 by Market Assessment (USD Mn), Yearly Growth Rate (%), and Market Presence (%)
- 13.1.1 NSAIDs
- 13.1.2 Opioids
- 13.1.3 Anesthetics
- 13.1.4 Other Analgesics
- 13.2.1 Dogs
- 13.2.2 Cats
- 13.2.3 Horses
- 13.2.4 Others
- 13.3.1 Veterinary Hospitals
- 13.3.2 Veterinary Clinics
- 13.3.3 Retail Pharmacies
- 13.3.4 Online Pharmacies
- 13.4.1 Saudi Arabia
- 13.4.2 UAE
- 13.4.3 South Africa
- 13.4.4 Egypt
- 13.4.5 Israel
- 13.4.6 Rest of Middle East and Africa
13.6 Regional Trends Analysis
13.7 Middle East & Africa Global Veterinary Pain Management Market Research Report - Company Profiles- 13.7.1 Company 1 (Saudi Arabia)
- 13.7.2 Company 2 (UAE)
- 13.7.3 Company 3 (UAE)
- 14.1 Strategic Dashboard of Top Market Players
14.2 Company Profiles (Introduction, Financial Assessments, Portfolio of Offerings, Milestones and Achievements, Strategic Initiative, and SWOT Analysis)- 14.2.1 Ceva
- 14.2.2 Elanco
- 14.2.3 Zoetis
- 14.2.4 Vetoquinol
- 14.2.5 Boehringer Ingelheim International GmbH
16. Principal Presumptions and Acronyms